Cardiology, Surgery. Company has developed an implantable heart device for treatment of myocardial infarction and other heart diseases where there is a dilation of the heart that leads to a loss of heart function. The company’s product is a minimally invasive percutaneous implant that serves as a partitioning membrane that isolates and decreases the volume in the hearts ventricles, ultimately restoring heart function and increasing cardiac output. Treatment of ischemic heart disease represents a $3 billion market, and current methodologies are not appropriate for many ischemic heart failure patients. The company obtained positive initial clinical data from its European feasibility trial and is actively enrolling patients for its ongoing U.S. pivotal trials. Founded: 2003.